Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 4/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | ACP3 | P15309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265486 | 0.86 | IDO1 (0.52) | ACHERXRARXRBRXRGIDO1 | |
| SCHEMBL21945061 | 0.83 | IDO1 (0.50) | IDO1TACR1CES2GABRA1GABRB2 | |
| SCHEMBL21944995 | 0.83 | IDO1 (0.50) | ACHERXRARXRBRXRGIDO1 | |
| SCHEMBL30056909 | 0.81 | IDO1 (0.44) | IDO1PTGS1TACR1KIF11GABRA1 | |
| SCHEMBL2456646 | 0.81 | IDO1 (0.48) | ACHEIDO1PTGS1TACR1 | |
| SCHEMBL13070067 | 0.81 | IDO1 (0.44) | IDO1PTGS1TACR1KIF11GABRA1 | |
| SCHEMBL17703931 | 0.81 | IDO1 (0.44) | ACHEIDO1PTGS1TACR1KIF11 | |
| SCHEMBL29876769 | 0.78 | RXRA (0.46) | ACHERXRARXRBRXRGIDO1 | |
| SCHEMBL3279035 | 0.78 | RXRA (0.46) | ACHERXRARXRBRXRGIDO1 | |
| SCHEMBL12115600 | 0.78 | GABRA1 (0.62) | ACHERXRARXRBRXRGGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941148-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | ACHE 3441/4885RXRA 1508/4885RXRB 1095/4885 |
| US-20190315754-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | ACHE 3441/4885RXRA 1508/4885RXRB 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.